TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA. (12th June 2019) - Porcu, P.; Kim, Y.; Zinzani, P.; Sicard, H.; Azim, H.A.; Bagot, M.